Latest Boehringer Ingelheim Stories
OXFORD, England, January 14, 2015 /PRNewswire/ -- Oxford BioTherapeutics announces today that Boehringer Ingelheim has exercised an option to receive exclusive rights to
HEIDELBERG, Germany, January 5, 2015 /PRNewswire/ -- BioMed X announced today that they have entered into a collaboration agreement with Boehringer Ingelheim to establish
- Phase I study results presented at American Society of Hematology Annual Meeting RIDGEFIELD, Conn., Dec. 8, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Dec.
- Retrospective analysis of more than 38,000 patients shows PRADAXA is associated with lower rates of stroke and major bleeding compared to warfarin RIDGEFIELD, Conn., Nov.
- Effects of idarucizumab on an exploratory marker of blood clotting, presented at the American Heart Association's Scientific Sessions RIDGEFIELD, Conn., Nov.
- Jardiance® (empagliflozin) data results presented at the 2014 Scientific Sessions of the American Heart Association RIDGEFIELD, Conn. and INDIANAPOLIS, Nov.
- Small missiles, especially grape, canister, fragments of iron, and the like, when fired, as upon an enemy at close quarters.
- To fire mitraille at.